A platform for studying the transfer of Chlamydia pneumoniae infection between respiratory epithelium and phagocytes

Maarit Kortesoja1, Raluca Elena Trofin2, Leena Hanski1

  • 1Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014, Finland.

Insights

Chlamydia pneumoniae can spread from the respiratory tract to other sites via infected monocytes. A new assay models this transfer, aiding research into persistent infections and potential therapies.

Area of Science:

  • Microbiology
  • Cell Biology
  • Infectious Diseases

Background:

  • Chlamydia pneumoniae is an intracellular bacterium linked to chronic inflammatory diseases.
  • Infection spreads from the respiratory tract via monocytes/macrophages, where C. pneumoniae persists antibiotically.
  • Studying the epithelium-monocyte/macrophage transition requires novel in vitro models.

Purpose of the Study:

  • To develop a new in vitro bioassay for studying C. pneumoniae transfer from epithelial cells to monocytes.
  • To enable detailed investigations into the epithelium-monocyte/macrophage transition of C. pneumoniae infection.

Main Methods:

  • A coculture system using human respiratory epithelial (HL) cells and THP-1 monocytes was established.
  • C. pneumoniae-infected HL cells were co-cultured with THP-1 monocytes.
  • THP-1 cells were isolated using biotinylated HLA antibodies and magnetic beads; C. pneumoniae load was quantified via qPCR.

Main Results:

  • The assay demonstrated robustness with a Z' value of 0.6.
  • Mitogen-activated protein kinase (MAPK) inhibitors (JNK, p38, ERK) effectively suppressed C. pneumoniae transfer from HL to THP-1 cells.
  • MAPK inhibitors were identified as suitable positive controls, indicating they inhibit bacterial entry into THP-1 cells.

Conclusions:

  • The developed coculture system provides a robust method for studying C. pneumoniae epithelial-phagocyte transfer.
  • MAPK pathways are crucial for C. pneumoniae entry into monocytes, suggesting therapeutic targets.
  • This assay facilitates future research aimed at blocking C. pneumoniae dissemination and persistent infection.